Combined Biopsy Method Improves Prostate Cancer Diagnosis
By LabMedica International staff writers Posted on 16 Mar 2020 |
Image: Testing with combined biopsy method improves prostate cancer diagnosis (Photo courtesy of the National Institutes of Health Clinical Center).
Prostate cancer can vary widely in severity and its potential to spread. Low-grade prostate cancer is associated with a very low risk of cancer-specific death and often does not require treatment, whereas high-grade cancers are much more likely to spread and are responsible for most prostate cancer deaths. This makes the correct assessment of the cancer grade very important for treatment decisions.
Unlike biopsies for most other types of cancer, which target abnormalities found by imaging, systematic biopsy uses a non-targeted method of taking systematically spaced samples across the prostate gland to find a cancer. Because this method can potentially miss areas of cancer, doctors may then over treat a patient with low-grade disease, fearing there is high-grade disease they missed.
A team of medical scientists collaborating with the National Institutes of Health Clinical Center (Bethesda MD, USA) studied 2,103 men who had magnetic resonance imaging (MRI)-visible lesions underwent both MRI-targeted and systematic biopsies. Of these men, 1,312 were diagnosed with cancer and 404 underwent prostatectomy, a full removal of the prostate. By comparing diagnoses from systematic biopsy alone to systematic biopsy plus MRI-targeted biopsy, the team found that adding MRI-targeted biopsy to systematic biopsy led to 208 more cancer diagnoses than systematic biopsy alone. The addition of MRI-targeted biopsy also led to 458 upgrades, or changes in diagnosis to a more aggressive cancer, based on analysis of the biopsy tissue by histopathology.
The team also determined that combined biopsy provided more accurate diagnosis than MRI-targeted biopsies alone. Among the men who underwent prostatectomy, they found that systematic biopsy alone underdiagnosed about 40% and MRI-targeted biopsy alone underdiagnosed about 30% of the cancers, while combined biopsy underdiagnosed 14.4% of the cancers. In addition, while systematic biopsy underdiagnosed 16.8% and MRI-targeted biopsy underdiagnosed 8.7% of the most aggressive cancers, combined biopsy missed only 3.5% of the most aggressive cancers.
Peter Pinto, MD, of the Urologic Oncology Branch in NCI's Center for Cancer Research and senior author of the study, said, “With the addition of MRI-targeted biopsy to systematic biopsy, we can now identify the most lethal cancers within the prostate earlier, providing patients the potential for better treatment before the cancers spread.”
The authors concluded that among patients with MRI-visible lesions, combined biopsy led to more detection of all prostate cancers. However, MRI-targeted biopsy alone underestimated the histologic grade of some tumors. After radical prostatectomy, upgrades to grade group 3 or higher on histopathological analysis were substantially lower after combined biopsy. The study was published on March 5, 2020 in the journal The New England Journal of Medicine.
Related Links:
National Institutes of Health Clinical Center
Unlike biopsies for most other types of cancer, which target abnormalities found by imaging, systematic biopsy uses a non-targeted method of taking systematically spaced samples across the prostate gland to find a cancer. Because this method can potentially miss areas of cancer, doctors may then over treat a patient with low-grade disease, fearing there is high-grade disease they missed.
A team of medical scientists collaborating with the National Institutes of Health Clinical Center (Bethesda MD, USA) studied 2,103 men who had magnetic resonance imaging (MRI)-visible lesions underwent both MRI-targeted and systematic biopsies. Of these men, 1,312 were diagnosed with cancer and 404 underwent prostatectomy, a full removal of the prostate. By comparing diagnoses from systematic biopsy alone to systematic biopsy plus MRI-targeted biopsy, the team found that adding MRI-targeted biopsy to systematic biopsy led to 208 more cancer diagnoses than systematic biopsy alone. The addition of MRI-targeted biopsy also led to 458 upgrades, or changes in diagnosis to a more aggressive cancer, based on analysis of the biopsy tissue by histopathology.
The team also determined that combined biopsy provided more accurate diagnosis than MRI-targeted biopsies alone. Among the men who underwent prostatectomy, they found that systematic biopsy alone underdiagnosed about 40% and MRI-targeted biopsy alone underdiagnosed about 30% of the cancers, while combined biopsy underdiagnosed 14.4% of the cancers. In addition, while systematic biopsy underdiagnosed 16.8% and MRI-targeted biopsy underdiagnosed 8.7% of the most aggressive cancers, combined biopsy missed only 3.5% of the most aggressive cancers.
Peter Pinto, MD, of the Urologic Oncology Branch in NCI's Center for Cancer Research and senior author of the study, said, “With the addition of MRI-targeted biopsy to systematic biopsy, we can now identify the most lethal cancers within the prostate earlier, providing patients the potential for better treatment before the cancers spread.”
The authors concluded that among patients with MRI-visible lesions, combined biopsy led to more detection of all prostate cancers. However, MRI-targeted biopsy alone underestimated the histologic grade of some tumors. After radical prostatectomy, upgrades to grade group 3 or higher on histopathological analysis were substantially lower after combined biopsy. The study was published on March 5, 2020 in the journal The New England Journal of Medicine.
Related Links:
National Institutes of Health Clinical Center
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes